Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q4 2021 · 10-K
Revenue$442.00K$442.00K— vs Q4 2020 Net Income-$6.21M-$6.21MN/M vs Q4 2020 EPS Diluted-$0.20-$0.20N/M vs Q4 2020 Operating Income-$6,219,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,307,400— Margins · derivedOperating margin-1407.0%
Net margin-1405.2%
ended Mar 31, 2021 · filed Jun 29, 2021 · 90 d after period end